Latest Headlines

  1. KAUST Researchers Develop Technology That Could Make Cancer Diagnosis Faster 6/15/2026

    Scientists at King Abdullah University of Science and Technology (KAUST) have developed a new stain-free imaging platform designed to analyze tissue samples more quickly and consistently, supporting future AI-assisted cancer diagnostics. 

  2. QIAGEN Expands QIAcuity Gene Expression Portfolio To Accelerate Digital PCR Adoption Across Research And Biopharma 6/15/2026

    QIAGEN N.V. today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications.

  3. Behemoth Labz Introduces Insights Into Growing Demand For COA Tested SARMs And Peptides In Research Applications 6/12/2026

    Behemoth Labz has introduced new insights regarding increasing demand for Certificate of Analysis (COA)-tested SARMs and Peptides within research-focused markets.

  4. Guardant Health Announces FDA Approval Of Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim's HERNEXEOS 6/11/2026

    Guardant Health, Inc., a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic (CDx) for Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets), the first targeted therapy for adults with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC) as an initial treatment option.

  5. Co-Diagnostics Advances Latin American Commercialization Strategy For Co-Dx™ PCR Pro® With Mexico Distributor Agreement 6/11/2026

    Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into an exclusive distribution agreement with its longstanding partner in Mexico for the Co-Dx™ PCR point-of-care platform*, including the PCR Pro® instrument and associated test kits, advancing the Company's strategy to expand its commercialization network and footprint in Latin America ahead of the platform's market launch, which remains subject to applicable regulatory review and authorization.

  6. Direct Replacements For Discontinued OEM Degasser Modules 6/10/2026

    Biotech Fluidics offer the most comprehensive range of degassing system products, enabling the company to provide open-framed degasser modules ready to be integrated into your fluidic instrumentation.

  7. Predicta Biosciences And CIMA LAB Diagnostics Announce Agreement To Advance Ultrasensitive Blood-Based Diagnostics For Multiple Myeloma And Other Hematological Malignancies 6/10/2026

    Predicta Biosciences, a company building ultra-sensitive molecular and immune diagnostic platforms, and CIMA LAB Diagnostics from the Clínica Universidad de Navarra, a leading European University Medical Center, today announced a partnership to offer a combined service that integrates CIMA LAB’s flow cytometry capabilities with the GenoPredicta assay.

  8. Watchmaker To Unveil New Technologies Addressing NGS Workflow Bottlenecks And Sequencing Accuracy Challenges At ESHG 2026 6/9/2026

    Watchmaker Genomics, a leader in high-performance NGS workflow solutions, today announced it will unveil two new technologies at the European Society of Human Genetics (ESHG) 2026 conference, designed to address persistent bottlenecks in sequencing workflow scalability and amplification accuracy.

  9. Personalis Enables Global Biopharma Support With CE-IVD Marked Specimen Collection Kits 6/9/2026

    Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union’s In Vitro Diagnostic Regulation (IVDR).

  10. Scispot Raises $8M Series A To Help Life Sciences Labs Move Faster 6/4/2026

    Scispot, the Canadian company behind the AI-native operating layer for modern labs, today announced an $8 million USD Series A led by Avenue Growth Partners, a Washington, DC-based investment firm.